DIABETES MELLITUS THERAPY. Nutrition Therapy  Weight loss frequently is a primary goal of nutrition therapy because 80% to 90% of people with type II.

Slides:



Advertisements
Similar presentations
Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Advertisements

University of Georgia Cooperative Extension. Why Change Eating Habits? To prevent complications of diabetesTo prevent complications of diabetes –by keeping.
Oral Hypoglycemic Drugs And Classifications
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
Managing Your Cholesterol 1. What is Cholesterol?  A waxy substance – technically a sterol (unsaturated steroid alcohol)  75% of your cholesterol is.
Control of Blood Sugar Diabetes Mellitus. Maintaining Glucose Homeostasis Goal is to maintain blood sugar levels between ~ 70 and 110 mg/dL Two hormones.
Diabetes. Diabetes Mellitus Disease in which the body doesn’t produce or properly use insulin, leading to hyperglycemia.
Oral Medications to Treat Type 2 Diabetes
Combination Therapy in Type 2 Diabetes
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
+ Were Hunters and Gatherers Really Healthier Than Us? An Evidence Based Look at the Paleolithic Diet By: Kelsey Starck.
LONG TERM BENEFITS OF ORAL AGENTS
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Hyperlipidemia Chapter 22. VIDEO There are four principal lipoprotein classes:lipoprotein 1. Chylomicrons are derived from intestinal absorption of exogenous.
Judith E. Brown Prof. Albia Dugger Miami-Dade College Diabetes Now Unit 13.
Diabetes Mellitus Diabetes Mellitus is a group of metabolic diseases characterized by elevated levels of glucose in blood (hyperglycemia) Diabetes Mellitus.
Treatment of diabetes:  Life style modification  Insulin  Oral hypoglycemic agents.
Management of Obesity and Dyslipidemia Presented by : Faisal Hassan Hussain.
CARE OF PATIENTS WITH DIABETES MELLITUS JANNA WICKHAM RN MSN LSSC FALL 2013 Chapter 20.
Copyright © 2005 Pearson Education, Inc., publishing as Benjamin Cummings The Role of Carbohydrates Energy – Sufficient energy from carbohydrates prevents.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Diabetes and You Vidya Sundaram, MD. Diabetes in Asian Indians The prevalence of diabetes in rural India is 2 percent The prevalence of diabetes in rural.
Nutrition Medical Therapy
Hypertension, Cardiovascular Disease, Diabetes. 34% of Americans 36% of Americans.
The Carbohydrates: Sugars, Starches, and Fiber Unit #4.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Diabetes mellitus (DM), also known simply as diabetes, is a group of metabolic diseases in which there are high blood sugar levels over a prolonged period.
5/26/2016 8:44 AM Reviewing Carbohydrates. 5/26/2016 8:44 AM Functions of Carbohydrates Why do we need them? Provide Energy Spare Protein Promote Normal.
Nutrition Guidelines. Nutrition Requirements: Types and Sources of Nutrients The nutrients are obtained when the foods we eat are digested into compounds.
Oral hypoglycemic drugs
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.
Diabetes- Chapter 49.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
DIABETIC TEACHING VERMALYNPAULETTEMICHELLEEDWARD.
Oral hypoglycemic drugs
Dixie L. Thompson chapter 20 Exercise and Diabetes.
Diabetes in Pregnancy Diabetes: a leading complication in pregnancy Forms of diabetes include: –Type 1 diabetes—Results from destruction of insulin-producing.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
Who is considered elderly? “Young old” years “Old, old” >75 years.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
นพ. เฉลิมศักดิ์ สุวิชัย โรงพยาบาล พะเยา. Management of Type 2 Diabetes Mellitus: A New Paradigm Approach Dr. Chalermsak Suwichai Phayao Hospital.
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Diabetes in the Pediatric Population
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Lecture on Anti Diabetic Drugs
Diabetes Mellitus Nursing Management.
The Carbohydrates: Sugar, Starch, Glycogen, and Fiber
Oral hypoglycemic drugs
Diabetes Mellitus.
Endocrine System KNH 411.
Drugs for Diabetes Mellitus
Endocrine System KNH 411.
Presented By: Sumia Khan
המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.
Diabetic Disorders 4th Leading cause of deaths in the US
oral hypoglycemic agents
Endocrine System KNH 411.
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
Presentation transcript:

DIABETES MELLITUS THERAPY

Nutrition Therapy  Weight loss frequently is a primary goal of nutrition therapy because 80% to 90% of people with type II diabetes are obese  Diet prescriptions for type II diabetes need to take into account the higher prevalence of hyperlipidemia, atherosclerosis, and hypertension in this population.

Protein Intake Recommended protein intake for patients with type II diabetes: 0.8 g/kg body weight/day Recommended protein intake for patients with type II diabetes: 0.8 g/kg body weight/day Protein allowance amounts 12% to 20% of daily calories and should be derived from both animal and vegetable sources. Protein allowance amounts 12% to 20% of daily calories and should be derived from both animal and vegetable sources.

80% to 90% of daily calories are distributed between fat and carbohydrate intake, based on a patient's nutrition assessment and treatment goals (glucose, lipid, and weight outcomes).

Fat Intake  Reduce dietary fat to < 35% of total calories  Limit saturated fat to < 10% of total calories, and < 7% of calories in patients with elevated LDL cholesterol  Limit polyunsaturated fats to 10% of total calories  Limit daily cholesterol consumption to 300 mg  Moderately increase intake of monounsaturated fats such as canola and olive oil (up to 20% of calories). A diet high in monounsaturated fats has been shown to improve glucose control, lower triglycerides, and raise HDL levels.

Carbohydrate Intake Emphasis is placed on whole grains, starches, fruits, and vegetables to provide the necessary vitamins, minerals, and fiber in the diet. Emphasis is placed on whole grains, starches, fruits, and vegetables to provide the necessary vitamins, minerals, and fiber in the diet. The recommended daily consumption of fiber is the same for people with diabetes as for nondiabetics (20 g to 35 g). The recommended daily consumption of fiber is the same for people with diabetes as for nondiabetics (20 g to 35 g).

Carbohydrate Intake Sucrose Sucrose  A modest amount of sugar is allowed in the daily diet of patients with type II diabetes. Obese individuals usually are advised to avoid sweets because of the potential of a small portion triggering overconsumption. Fructose Fructose  A natural source of dietary fructose is fruits and vegetables.  Moderate consumption is recommended, particularly concerning foods in which fructose is used as a sweetening agent.

Alcohol Intake Moderate consumption will not adversely affect blood glucose in patients whose diabetes is well controlled. Calories from alcohol should be included as part of the total calorie intake. Moderate consumption will not adversely affect blood glucose in patients whose diabetes is well controlled. Calories from alcohol should be included as part of the total calorie intake. For patients taking insulin, one or two alcoholic beverages per day are acceptable (one alcoholic beverage = 12 oz beer, 5 oz wine, or 1[ring] oz distilled spirits; sweet drinks should be avoided) For patients taking insulin, one or two alcoholic beverages per day are acceptable (one alcoholic beverage = 12 oz beer, 5 oz wine, or 1[ring] oz distilled spirits; sweet drinks should be avoided) Patients taking insulin or sulfonylureas are susceptible to hypoglycemia if alcohol is consumed on an empty stomach. Patients taking insulin or sulfonylureas are susceptible to hypoglycemia if alcohol is consumed on an empty stomach.

Oral Antidiabetic Agents  Oral medication is initiated when 3 months of diet and exercise alone are unable to achieve or maintain plasma glucose levels within these glycemic guidelines.  If patients are symptomatic, oral antidiabetic agents or insulin should be initiated in concert with diet and exercise.

Oral Antidiabetic Agents  Current therapy for the treatment of hyperglycemia of type II diabetes includes the following oral antidiabetic agents: Sulfonylureas Sulfonylureas Biguanides: metformin Biguanides: metformin Alpha-glucosidase inhibitors: acarbose Alpha-glucosidase inhibitors: acarbose Thiazoladinediones Thiazoladinediones Meglitinides Meglitinides

Oral Antidiabetic Agents In general, oral agents are contraindicated in patients who: In general, oral agents are contraindicated in patients who: Are pregnant or lactating Are pregnant or lactating Are seriously ill Are seriously ill Have significant kidney or liver disease Have significant kidney or liver disease Have demonstrated allergic reactions. Have demonstrated allergic reactions.

Sulfonylureas Sulfonylureas work primarily by stimulating pancreatic insulin secretion, which in turn reduces hepatic glucose output and increases peripheral glucose disposal. Sulfonylureas work primarily by stimulating pancreatic insulin secretion, which in turn reduces hepatic glucose output and increases peripheral glucose disposal. Examples of the compounds are: Examples of the compounds are: Glimepiride (Amaryl) Glimepiride (Amaryl) Glipizide Glipizide Glyburide Glyburide Gliclazide Gliclazide

Biguanides  Metformin is a biguanide that works mainly by:  Suppressing excessive hepatic glucose production  Increasing glucose utilization in peripheral tissues to a lesser degree  It may also improve glucose levels by reducing intestinal glucose absorption

Biguanides Metformin is effective as monotherapy or in combination with sulfonylureas, alpha-glucosidase inhibitors, and insulin Metformin is effective as monotherapy or in combination with sulfonylureas, alpha-glucosidase inhibitors, and insulin Treatment with metformin has beneficial effects on plasma lipids Treatment with metformin has beneficial effects on plasma lipids Metformin therapy has been associated with weight loss or no weight gain Metformin therapy has been associated with weight loss or no weight gain

Biguanides Contraindications: Contraindications:  renal failure  significant hepaticdisease  heart failure  alcohol abuse  any hypoxic condition or history of lactic acidosis

Biguanides  Lactic acidosis is a rare complication of metformin therapy and has a high mortality rate  In any patient who is hospitalized with an acute severe illness, metformin should be temporarily discontinued

Alpha-glucosidase inhibitors Acarbose slows down the breakdown of disaccharides and polysaccharides and other complex carbohydrates into monosaccharides slows down the breakdown of disaccharides and polysaccharides and other complex carbohydrates into monosaccharides t he enzymatic generation and subsequent absorption of glucose is delayed and the postprandial blood glucose values, which are characteristically high in patients with type II diabetes, are reduce d t he enzymatic generation and subsequent absorption of glucose is delayed and the postprandial blood glucose values, which are characteristically high in patients with type II diabetes, are reduce d

Thiazolidinediones (PPAR  -agonists) They work mainly by improving peripheral insulin resistance in skeletal muscle without stimulating insulin secretion. They work mainly by improving peripheral insulin resistance in skeletal muscle without stimulating insulin secretion. They works to a lesser degree by reducing excessive hepatic glucose production. They works to a lesser degree by reducing excessive hepatic glucose production. It also results in significant reduction in total triglyceride and elevation in HDL levels. It also results in significant reduction in total triglyceride and elevation in HDL levels.

Meglitinides  Examples: repaglinide, nataglinide  It is a benzoic acid derivative and a short-acting insulin releaser.  It stimulates the release of insulin from the pancreatic beta cells by closing ATP-sensitive potassium channels.  It has no significant effect on plasma lipid levels  Rapid onset and short duration of action make multiple daily doses necessary (take it immediately before each meal!).

Monotherapy With Oral Antidiabetic Agents Obese Patients With Newly Diagnosed Diabetes With/Without Dyslipidemia  Metformin or acarbose have the advantage of not inducing weight gain, which can occur with sulfonylureas and insulin therapy.

Monotherapy With Oral Antidiabetic Agents Thin Elderly Patients Thin patients in general tend to be insulin deficient and more commonly require sulfonylureas as initial oral monotherapy Thin patients in general tend to be insulin deficient and more commonly require sulfonylureas as initial oral monotherapy Caution should be used when prescribing any medication in the elderly, and starting doses need to be lower than those in younger patients Caution should be used when prescribing any medication in the elderly, and starting doses need to be lower than those in younger patients Rosiglitazone, acarbose and metformin may also be effective as monotherapy Rosiglitazone, acarbose and metformin may also be effective as monotherapy

Monotherapy With Oral Antidiabetic Agents Patients With Acceptable Fasting Glucose Values but Elevated Glycohemoglobin Levels It suggests the likelihood of elevated postprandial glucose levels It suggests the likelihood of elevated postprandial glucose levels Acarbose would be an appropriate choice in these patients ( by reducing the postprandial glucose value) Acarbose would be an appropriate choice in these patients ( by reducing the postprandial glucose value) If acarbose is not indicated or tolerated, rosiglitazone, metformin, or sulfonylurea may be effective. If acarbose is not indicated or tolerated, rosiglitazone, metformin, or sulfonylurea may be effective.

Monotherapy With Oral Antidiabetic Agents Nonobese Individuals With Diabetes Lean patients with mild glucose intolerance can be given a trial with any of the four classes of oral agents Lean patients with mild glucose intolerance can be given a trial with any of the four classes of oral agents Sulfonylureas are likely to be a better choice for patients when blood glucose values are consistently in the 200 to 300 mg/dL range (these drugs can be titrated more rapidly to higher doses, which may be necessary in this patient group). Sulfonylureas are likely to be a better choice for patients when blood glucose values are consistently in the 200 to 300 mg/dL range (these drugs can be titrated more rapidly to higher doses, which may be necessary in this patient group).

Monotherapy With Oral Antidiabetic Agents Patients With Prolonged, Severe Hyperglycemia (Glucose Toxicity) a temporary trial of insulin therapy should be instituted for a few weeks before beginning an oral agent to reduce insulin resistance and improve endogenous insulin secretory capacity a temporary trial of insulin therapy should be instituted for a few weeks before beginning an oral agent to reduce insulin resistance and improve endogenous insulin secretory capacity start a sulfonylurea agent at the maximum dose and follow the patient carefully start a sulfonylurea agent at the maximum dose and follow the patient carefully once metabolic control is achieved the glucose toxic state improves. At this point, switching to other oral agents with less hypoglycemic potential is a reasonable alternative once metabolic control is achieved the glucose toxic state improves. At this point, switching to other oral agents with less hypoglycemic potential is a reasonable alternative

Monotherapy With Oral Antidiabetic Agents Patients With Severe Renal or Liver Dysfunction Both sulfonylureas and metformin should be used with caution Both sulfonylureas and metformin should be used with caution In patients with renal impairment, acarbose or rosiglitazone represent an excellent choice In patients with renal impairment, acarbose or rosiglitazone represent an excellent choice In patients with significant or progressive liver disease, hyperglycemia is best treated with exogenous insulin alone. In patients with significant or progressive liver disease, hyperglycemia is best treated with exogenous insulin alone.

DIABETES MELLITUS GOALS OF THERAPY (EDPG 1998) FASTING PLASMA GLUCOSE: < 100 mg/dL POSTPRANDIAL PLASMA GLUCOSE: < 135 mg/dL HbA1c: < 6,5% HbA1c: < 6,5%

DIABETES MELLITUS GOALS OF THERAPY (EDPG 1998) Total cholesterol: < 185 mg/dL Total cholesterol: < 185 mg/dL LDL-cholesterol: < 115 mg/dL LDL-cholesterol: < 115 mg/dL HDL-cholesterol: > 46 mg/dL HDL-cholesterol: > 46 mg/dL Triglycerides: < 150 mg/dL Triglycerides: < 150 mg/dL Blood pressure: < 140/85 mm Hg Blood pressure: < 140/85 mm Hg

DIABETES MELLITUS GOALS OF THERAPY Negative Urine glucose Negative Urine Ketones Symptomatic Improvement Normalize Nutrition Avoid/Prevent Complications